Navidea Biopharmaceuticals (NYSE:NAVB) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVBFree Report) in a research report released on Friday morning. The firm issued a sell rating on the stock.

Navidea Biopharmaceuticals Stock Performance

Shares of Navidea Biopharmaceuticals stock opened at $0.04 on Friday. The firm has a market capitalization of $3.50 million, a PE ratio of -0.58 and a beta of 1.15. The business’s 50-day moving average price is $0.05 and its 200-day moving average price is $0.07. Navidea Biopharmaceuticals has a 12 month low of $0.02 and a 12 month high of $0.34.

Navidea Biopharmaceuticals (NYSE:NAVBGet Free Report) last posted its quarterly earnings results on Tuesday, November 14th. The company reported ($0.02) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Navidea Biopharmaceuticals

A hedge fund recently raised its stake in Navidea Biopharmaceuticals stock. State Street Corp grew its holdings in Navidea Biopharmaceuticals, Inc. (NYSE:NAVBFree Report) by 1,631.1% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 412,743 shares of the company’s stock after purchasing an additional 388,900 shares during the period. State Street Corp owned about 1.18% of Navidea Biopharmaceuticals worth $38,000 as of its most recent SEC filing. Institutional investors and hedge funds own 15.75% of the company’s stock.

About Navidea Biopharmaceuticals

(Get Free Report)

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases.

See Also

Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.